Business
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high...
About this update from Seres Therapeutics, Inc.
[{"type":"image","alt":"Seres Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Seres Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":205,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c9212fd90ce8aaab0f99113fa1623d37"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k2NwaR5ktGr5v1rR6gsPpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE0OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c9212fd90ce8aaab0f99113fa1623d37","width":205,"height":85}},"lazy":false},{"type":"text","content":"Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients","length":122,"tagName":"p"},{"type":"text","content":"Seres MbTx® platform provides high-resolution functional biological understanding of live biotherapeutics and supports the advancement of Seres’ portfolio, including Phase 2-ready lead candidate SER-155","length":202,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced the publication of two manuscripts in Nature Medicine and the Journal of Infectious Diseases highlighting new insights into the functional mechanism and clinical impact of VOWST™. Together, these publications provide further validation of the Company’s Live Biotherapeutics Products (LBPs) approach and inform the continued development of Seres’ pipeline of next-generation LBPs, including its lead investigational candidate, SER-155.","length":583,"tagName":"p"},{"type":"text","content":"Seres led the development and FDA approval of VOWST™, a rationally selected consortia of bacteria in oral capsules that was designed to have specific functional pharmacological properties with clinical translation of these MoAs observed in the ECOSPOR III and IV Phase 3 trials. VOWST was the first-ever oral microbiome biotherapeutic licensed by the FDA, with approval in April 2023 for the prevention of recurrent Clostridioides difficile (rCDI) infection. VOWST was sold to Nestlé Health Science in September 2024.","length":517,"tagName":"p"},{"type":"text","content":"The Nature Medicine article, titled “The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome”, confirmed Seres pharmacological hypotheses from earlier ...